Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?

Plain-language summary

This study investigated whether there is a relationship between the level of anti-p53 antibody in the blood and the PET parameters TLG, MTV and SUV obtained from 18F-FDG PET/CT imaging in patients with lung cancer. Blood samples were collected; patients imaged for staging after a lung cancer diagnosis were compared with healthy individuals. It was conducted as a non-phase observational study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Cumhuriyet University

Intervention

Blood Collection

Start date

5/1/2014

Estimated completion

4/1/2016

Countries

Turkey (Türkiye)

Related genes

Locations

• Sivas, Turkey (Türkiye)

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* patients who were referred to our department with the purpose of 18F-FDG PET/CT imaging for staging due to lung cancer diagnosis
* patients who were performed 18F-FDG PET/CT for diagnosis in the cause of the suspected pulmonary nodule/lesion in thorax CT but not detected pathologic FDG accumulation
* In the control group, healthy subjects with no history of cancer and without any complaint

Exclusion Criteria:

* Patients had operated for lung cancer, received prior chemotherapy or radiotherapy for lung cancer, with no definitive histological diagnosis, and a blood glucose level greater than 150 mg/dL